Exact Sciences Corporation (EXAS): Debt Offering News

EXAS – Upsizes offering by $100 mln and prices of $600 mln of 1.0% Convertible Senior Notes due 2025.

Key Facts Surrounding This News Item

  • EXAS had a POWR Rating of B (Buy) coming into today.
  • EXAS was 1.99% above its 10-Day Moving Average coming into today.
  • EXAS was 3.27% above its 20-Day Moving Average coming into today.
  • EXAS was -0.92% below its 50-Day Moving Average coming into today.
  • EXAS was 9.33% above its 100-Day Moving Average coming into today.
  • EXAS was 31.92% above its 200-Day Moving Average coming into today.
  • EXAS had returned +4.80% year-to-date leading up to today’s news, versus a +3.47% return from the benchmark S&P 500 during the same period.

More Info About Exact Sciences Corporation (EXAS)

Exact Sciences is a molecular diagnostics company focused on gastrointestinal cancers. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. The company was founded in 1995 and is based in Madison, Wisconsin. View our full EXAS ticker page with ratings, news, and more.

EXAS at a Glance

EXAS Current POWR Rating™
Overall POWR Rating™
EXAS Current Price $78.80 4.19%
More EXAS Ratings, Data, and News

EXAS Price Reaction

The day of this event (Jan. 12, 2018)
EXAS Closing Price$52.62 4.43%
EXAS Volume6,363,000
162.82% from avg
Leading up to this event
EXAS 1-mo return9.64%
After this event
EXAS 1-day return3.98%
EXAS 3-day return12.85%
EXAS 5-day return13.55%

EXAS Price Chart

The Top Stocks For 2019

More Exact Sciences Corporation (EXAS) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All EXAS News
Page generated in 0.9673 seconds.